www.vanderbilthealth.com/main/www.mc.vanderbilt.edu

Active Research Grants

National Institutes of Mental Health (NIMH)

Selective M1 mAChR allosteric modulators for the treatment of schizophrenia (5R01MH082867-02)

Vanderbilt NCDDDG (National Cooperative Drug Discovery and Development Groups) for Discovery of Novel Treatments for Schizophrenia (1U01MH087965-01)


National Institutes of Drug Abuse (NIDA)

Partial antagonists of mGluR5 for the treatment of cocaine addiction (5R01DA023947-02)>


Molecular Libraries Program (MLPCN/NIMH)

The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (5U54MH084659-02)


Michael J. Fox Foundation LEAPS Award

mGluR4 PAMs for Parkinson's Disease


Alzheimer’s Association (IIRG)

Novel Muscarinic Therapeutics for Alzheimer's Disease


Corporate Partnerships

Seaside Therapeutics

Collaborative Drug Discovery - Fragile X Syndrome

Johnson & Johnson

mGluR5 Positive Allosteric Modulators for Schizophrenia


Others

American Cancer Society (IIRG)

AMGEN

Eisai